Peptidomimetic-based antibody surrogate for HER2.

Author: Mengmeng ZHENG ¹ ; Chunpu LI ¹ ; Mi ZHOU ¹ ; Ru JIA ² ; Fengyu SHE ¹ ; Lulu WEI ¹ ; Feng CHENG ³ ; Qi LI ² ; Jianfeng CAI ¹ ; Yan WANG ²
Author Information

1. Department of Chemistry, University of South Florida, Tampa, FL 33620, USA.
2. Department of Medical Oncology & Cancer Institute of Medicine, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
3. Department of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA.
Publication Type:Journal Article
Keywords: Anti-cancer; Antibody-surrogate; HER2; Peptidomimetics; γ-AApeptides
From: Acta Pharmaceutica Sinica B 2021;11(9):2645-2654
CountryChina
Language:English
Abstract: Inhibition of human epidermal growth factor receptor 2 mediated cell signaling pathway is an important therapeutic strategy for HER2-positive cancers. Although monoclonal antibodies are currently used as marketed drugs, their large molecular weight, high cost of production and susceptibility to proteolysis could be a hurdle for long-term application. In this study, we reported a strategy for the development of artificial antibody based on